stockrowArcus Biosciences, Inc. (RCUS) vs Recursion Pharmaceuticals, Inc. (RXRX)
- Arcus Biosciences, Inc. RCUS 18.34 +3.67%
- Recursion Pharmaceuticals, Inc. RXRX 3.59 +2.57%
Arcus Biosciences, Inc. and Recursion Pharmaceuticals, Inc. are both Biotechnology companies. Arcus Biosciences, Inc. is the larger, with a market value of $2.5B against $2.2B — 1.2× the size. Recursion Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 56.2% against −58.3%. Arcus Biosciences, Inc. has the higher net margin (−453.0% vs −697.1%) and the higher return on invested capital (0.00% vs −88.5%). Across the 18 metrics below, Recursion Pharmaceuticals, Inc. leads on 11 and Arcus Biosciences, Inc. on 7.
Valuation
Profitability
| Metric | RCUS | RXRX | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 29.21% | 65.16% |
| Operating margin | (475.00%) | (725.44%) | 0.00% |
| Net margin | (453.00%) | (697.13%) | 0.00% |
| Free cash flow margin | (465.00%) | (460.89%) | 0.00% |
| Return on equity | (114.11%) | (48.72%) | (50.12%) |
| Return on assets | (50.56%) | (36.29%) | (45.60%) |
| Return on invested capital | 0.00% | (88.54%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack